Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone - Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI Summary - About
Corbus Pharmaceuticals Holding(CRBP)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Stock price based on last close Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CRBP
11/12/2026: CRBP (2-star) is currently NOT-A-BUY. Pass it for now.
Corbus Pharmaceuticals is a clinical-stage biotechnology company that has pivoted to focus on precision oncology, specifically antibody-drug conjugates. Its main strength lies in a specialized, modern R&D approach aimed at high-value cancer targets, which offers significant growth potential if trials succeed. However, the company is not currently profitable and faces high risks related to clinical execution, capital dependency, and intense competition from well-funded pharmaceutical firms. This stock is best suited for speculative, high-risk growth investors who closely monitor clinical data milestones. Potential investors should watch for trial results and possible licensing partnerships as key indicators of future stability.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Mixed fit | While the company has high growth potential through its clinical pipeline, the binary risk of drug development makes it speculative. |
| Momentum investor | Strong fit while signal remains positive | Momentum investors may find opportunities around clinical trial data releases and share price catalysts. |
| Value investor | Weak fit | The company lacks current earnings or revenue, making traditional value metrics inapplicable. |
| Dividend investor | Weak fit | Corbus does not pay a dividend and focuses entirely on capital reinvestment. |
| Low-risk investor | Weak fit | The volatility and risk of clinical-stage biotech development are incompatible with low-risk portfolios. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Clinical trial results can lead to drastic, rapid changes in share price. |
| Valuation risk | High | Without revenue, valuation is highly subjective and depends on pipeline progress projections. |
| Competition risk (oncology therapeutics) | High | The oncology field is crowded with better-funded competitors working on similar targets. |
| Business quality | Medium | The quality is driven by the strength of the scientific pipeline rather than operational cash flows. |
| Dividend income | Low / none | There is no income potential from dividends. |
| Execution risk | High | Successfully taking a drug from early-stage to regulatory approval is exceptionally difficult. |
Price Behavior
Steep Decline
The stock price has dropped sharply with strong downward pressure.
Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 226.23% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Advisory Rating  | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 11/12/2026 |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals
Financial Health Rating
Growth Momentum Score
Ownership
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue)
Economic Dimensions
Quantitative Style Profile
Style Classification
Quality Focused
Sector & Industry Intelligence
Sector snapshot as of 2026-11-10
Sector
Healthcare
- Signal
- Constructive
- Sentiment
- Strong Bullish
- Market state
- Strong Bullish
- Momentum
- BUY Breadth Improving
- BUY participation
- 60.0%
- Active BUY / eligible
- 69 / 115
- 22-session BUY-count change
- +29
More qualifying stocks are receiving or maintaining BUY advisories, indicating improving market participation.
Industry
Biotechnology
- BUY participation
- 43.5%
- Active BUY / eligible
- 20 / 46
- 22-session BUY-count change
- +12
The sector signal does not change this stock’s BUY, SELL, or PASS advisory.
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 82.43M USD | Price to earnings Ratio - | 1Y Target Price 33.22 |
Price to earnings Ratio - | 1Y Target Price 33.22 | ||
Volume (30-day avg) 1.1M shares | Beta 2.79 | 52 Weeks Range 2.81 - 12.88 | Updated Date 11/12/2026 |
52 Weeks Range 2.81 - 12.88 | Updated Date 11/12/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) -6.04 |
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Oncology Research & Development | Clinical trial development and licensing of precision medicine assets. | The company is currently spending money to invent new drugs; they will make money if a drug is approved or licensed. |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -28.79M | Price to Sales(TTM) 169.88 |
Enterprise Value -28.79M | Price to Sales(TTM) 169.88 | ||
Enterprise Value to Revenue 4531.61 | Enterprise Value to EBITDA 0.17 | Shares Outstanding 20.61M | Shares Floating 15.02M |
Shares Outstanding 20.61M | Shares Floating 15.02M | ||
Percent Insiders 1.16 | Percent Institutions 69.76 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.